At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.
About The Author
April 5, 2018
October 29, 2017
The Bank of New York Mellon Corporation’s (NYSE:BK) Earnings Grew 14.79%, Did It Beat Long-Term Trend?
March 31, 2018